Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer

MDA-MB-231 and MCF7 cancer cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). MDA-MB-468 cells were kindly provided by Dr C. Gilles (University of Liège, Belgium). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Lonza) containing 10% fetal bovine serum (FBS, ThermoFisher Scientific) and 2 mM L-glutamine (Lonza). For cell signaling analysis, cells were cultured in DMEM with L-glutamine and without FBS. L-carnosine (C9625), aminoguanidine (396494) and methylglyoxal (MG, M0252) were from Sigma. We excluded the presence of significant formaldehyde contamination (< 3%) in MG (lot #BCBQ9416V) by nuclear magnetic resonance (NMR) analysis. Transforming growth factor (TGF)β (#10021) was from Peprotech. U0126 (S1102) was from Selleckchem. Anti-argpyrimidine antibody (mAb6B) specificity has been previously confirmed by competitive enzyme-linked immunosorbent assay (ELISA) and shown to not react with other MG-arginine adducts [13].

MG measurements were performed as previously described [12]. Briefly, culture medium was collected from GLO1-silenced MDA-MB-231 cells and the corresponding attached cells were counted to normalize MG measurements. Levels of MG were determined by derivatization with O-phenylenediamine (oPD) and analyzed by stable isotope dilution ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) as described previously [14].

IHC was performed using a standard protocol as described previously [12] using the following antibodies: anti-vimentin (1:4, clone V9, Ventana Medical Systems), anti-tenascin C (1:1000, ThermoFisher Scientific) and anti-collagen VI α3 (1:200, Sigma). Positive cells were visualized using a 3,3′-diaminobenzidine substrate and the sections were counterstained with hematoxylin. Tissue sections incubated without primary antibody showed no detectable immunoreactivity. Tissue was stained with hematoxylin eosin and Masson's trichrome using standard protocols.

For vimentin IHC, three different whole immunolabeled tissue sections per lung were digitalized at high resolution (Ventana iScan HT, Ventana Medical Systems). Vimentin-positive metastatic cells were quantified by computerized counts (QuPath 0.1.2 open source software) and verified by manual counting. The number of positive cells to lung area was reported, yielding a count expressed as the number of cells per square millimeter. For tenascin C IHC and Masson’s trichrome staining, a score of 0 was associated with negative staining and a score of 1 with positive staining in tumor cells.

Standard protocols are detailed in Additional file 1: Supplementary methods.

Collagen gels were made as previously described [15]. Briefly, DMEM containing 10% fetal calf serum (FCS) was prepared at the appropriate concentration and at pH 8.3 to accommodate the addition of bovine skin collagen (3 mg/ml final concentration) in HAc 0.1% and MDA-MB-231 (300.000 cells/gel). After polymerization of the collagen, the gels were detached from the walls of the dishes by gentle tapping and swirling. Gel diameter was measured at regular intervals and collagen gel areas were calculated.

MDA-MB-231 and MDA-MB-468 cells (2 × 10⁵ cells) were suspended in serum-free DMEM medium (0.1% bovine serum albumin (BSA), 1% penicillin/streptomycin (pen/strep)) and seeded into the upper part of Transwell filters (pore size 8 μm, Costar) for migration or Transwell filters precoated with Matrigel for invasion (BD Biosciences). The lower compartment was filled with DMEM containing 1% BSA, 1% pen/strep and 10% FBS. After 16 h or 24 h incubation at 37 °C for migration and invasion, respectively, migrating cells were stained with Diff-Quick (Medion Diagnostics). Inserts were scanned at 10× magnification (Eclipse Ti, Nikon). The area covered by migrating/invading cells was quantified by densitometry (ImageJ). Data are expressed as relative migration/invasion ability compared to control cells.

MCF7 (15,000 cells/well) and MCF7-M (60,000 cells/well) cells were seeded in Seahorse XFp mini-plates (Agilent) and analyzed using the Seahorse glycolysis stress test according to manufacturer’s recommendations. Cells were first challenged with glucose (10 mM) then successively stressed with oligomycin (1 μM) and 2-deoxyglucose (50 mM). All results were normalized to protein quantification.

Cells were incubated in glucose-free medium in the presence of 2-NBDG (ThermoFisher Scientific) for 30 min and further analyzed by flow cytometry (BD Biosciences). Median fluorescence intensity (MFI) was calculated.

GLO1 activity was assessed as previously described [7]. Briefly, proteins were extracted with radioimmunoprecipitation (RIPA) buffer, quantified and mixed with a pre-incubated (15 min at 25 °C) equimolar (1 mM) mixture of MG and GSH (Sigma) in 50 mM sodium phosphate buffer, pH 6.8. S-D-lactoylglutathione formation was followed spectrophotometrically by the increase in absorbance at 240 nm at 25 °C. GLO1 activity data are expressed as arbitrary units (A.U.) of enzyme per milligram of proteins.

Data from two groups were compared using the unpaired Student’s t test with or without Welsch’s correction according to homoscedasticity. Experimental data from more than two groups were compared using one-way or two-way analysis of variance (ANOVA) depending on the number of grouping factors. Dunnett’s test was applied for simple comparisons while Student-Newman-Keul’s (one-way ANOVA) or Bonferroni’s (two-way ANOVA) tests were used for multiple comparisons. In the case of discrete variables (IHC scores) or non-normally distributed variables, groups were compared using Mann-Whitney’s U test. Outliers were detected using whisker box plots. A bilateral p value <0.05 was considered statistically significant with a 95% confidence interval.

In an attempt to unveil the mechanisms by which MG stress enhances the metastatic potential of breast cancer cells, we performed genome-wide messenger RNA (mRNA) profiling of MDA-MB-231 GLO1-depleted cells. We first validated GLO1 depletion by western blot and the subsequent increased MG production in stably GLO1-silenced MDA-MB-231 cells (Fig. 1a and Additional file 2: Figure S1A). Using a workflow consisting of RNASeq followed by ToppFun analysis (Fig. 1b), we have identified 809 and 738 genes that were significantly differentially expressed in shGLO1#1 and #2, respectively, when compared to control cells. ShGLO1#1 and #2 clones had consistent gene modulation and overall good correlation (Fig. 1c and Additional file 2: Figure S1B). Among differentially expressed genes, 337 genes were common to both shGLO1 clones, among which 323 genes were consistently up-regulated or down-regulated (Fig. 1d). Based on Gene Ontology analysis, differentially expressed genes were associated with key steps in the metastatic cascade including cell adhesion, migration and ECM reorganization (Fig. 1e). Globally, 196 and 184 significantly modulated genes were linked to migration and adhesion processes in shGLO1#1 and #2, respectively. The combination of these two sets of genes resulted in a unique dicarbonyl stress signature consisting of 296 genes related to the pro-metastatic behavior of breast cancer cells, with 89 differentially expressed genes common between the two shGLO1 clones (Fig. 1f).

We validated the expression level of remarkable up-regulated and down-regulated genes known to be linked to the metastatic potential of cancer cells (Additional file 2: Table S1). Using RT-qPCR, tenascin C and CD24 mRNA levels proved to be significantly overexpressed in GLO1-depleted cells (Fig. 1g). Lumican, a small leucine-rich proteoglycan the down-regulation of which has been associated with lung invasion in different cancer types, was significantly inhibited at the mRNA level upon MG stress (Fig. 1g). In order to demonstrate that MG stress directly regulates the expression of these genes, we treated MDA-MB-231 cells with MG. Similar to GLO1 silencing, MG treatment significantly increased tenascin C and CD24 mRNA levels and decreased lumican mRNA level (Additional file 2: Figure S1C). At the protein level, tenascin C overexpression was evidenced in both total protein extracts and secreted proteins deposited by cultured GLO1-depleted cells (Fig. 1h) while increased CD24 cell surface expression was confirmed using fluorescence-activated cell sorting (FACS) analysis (Fig. 1i). TGFBI, an RGD-containing ECM protein that binds to collagens, was also increased in GLO1-silenced MDA-MB-231 cells (Fig. 1j). The decrease in type IV collagens (COL4A3 and COL4A4) associated with an increase in type VI collagens (COL6A1, COL6A2 and COL6A3) particularly attracted our attention (Additional file 2: Table S1). Indeed, this inverse regulation has been linked to cancer progression and metastasis [16]. We validated this specific modulation of collagen gene expression in cancer cells upon GLO1 depletion at both mRNA (Fig. 2a) and protein (Fig. 2b and c) levels. To the best of our knowledge, this is the first evidence of the contribution of endogenous MG stress to ECM composition directly by breast cancer cells.

The well-established role of ECM remodeling in structuring a microenvironment favoring cancer cell progression prompted us to explore the behavior of high MG stress cancer cells using the collagen gel retraction assay, an in vitro model well-suited to study cell-mediated reorganization of the ECM. Accordingly, we analyzed the capacity of GLO1-silenced MDA-MB-231 cells to compact collagen fibers in the presence of 10% FCS. After 6 days, GLO1 deficient cells induced significantly higher collagen gel retraction than control cells (Fig. 2d and e). Anchorage-independent growth ability of breast cancer cells correlates with their metastatic ability [17]. In anchorage-independent assays, GLO1-silenced MDA-MB-231 cells formed significantly more colonies than control cells and this difference was abrogated by the natural MG scavenger carnosine (Fig. 2f and Additional file 2: Figure S2).

To test the relevance of the pro-metastatic MG stress signature in vivo, we decided to use the tail vein injection mouse model that recapitulates the major steps of the metastatic cascade (migration/invasion, proliferation and survival) independently from the growth of the primary tumor. We observed that GLO1-depleted cells injected into the tail vein of NOD-SCID mice induced a significant increase in pulmonary tumor burden when compared with control (Fig. 3a). In the same model, carnosine intra-peritoneal administration significantly reduced lung colonization thus connecting this aggressive characteristic with MG stress (Fig. 3a and b). Finally, IHC for tenascin C and collagen deposition assessed by Masson’s trichrome staining in metastatic lung sections showed high detectable levels of both ECM components (Fig. 3c and d), which were consistently lower in metastatic foci of carnosine-treated mice (Fig. 3d). Next, we examined whether enhanced anchorage-independence growth and metastatic potential (i.e., lung colonization) of GLO1-depleted cells correlated with increased invasion and migration ability in vitro.

The migratory ability of GLO1-depleted cancer cells increased up to 2.5-fold compared with control cells (Fig. 4a and b). This increased migratory ability was reversed by overexpressing GLO1 in shGLO1#1 MDA-MB-231 cells (Additional file 2: Figure S3A and B). GLO1 rescue was evaluated by western blot (Additional file 2: Figure S3C). Additionally, the pre-treatment of GLO1-depleted cells with carnosine and aminoguanidine, MG scavengers, decreased their migration to control level (Fig. 4a and b). GLO1 depletion was also significantly associated with augmented invasive potential in vitro, which was efficiently reversed by pre-treatment with both scavengers (Additional file 2: Figure S3D and E). To exclude the possibility of this MG-induced effect being anecdotal to MDA-MB-231 cells, we exploited a model of highly tumorigenic and motile MCF7-M breast cancer cells, generated by prolonged mammosphere culture. In good accordance with previous reports [18, 19], MCF7-M cells exhibited a stable mesenchymal phenotype (Fig. 4c and Additional file 2: Figure S4A), enhanced glycolysis (Fig. 4d and Additional file 2: Figure S4B) and glucose uptake (Fig. 4e). We first demonstrated that MCF7-M cells were associated with significantly higher accumulation of MG-Hs and argpyrimidine adducts than in the control parental MCF7 cells (Fig. 4f). These data are consistent with our recent demonstration that glycolytic cancer cells are more prone to control MG toxicity than less glycolytic cancer cells, notably through the expression of elevated levels of both GLO1 and its cognate transcriptional regulator Nrf2 [9]. Accordingly, MCF7-M had a high GLO1 protein level and activity and elevated Nrf2 expression when compared with MCF7 cells (Fig. 4g and h). Finally, on treatment with carnosine and aminoguanidine, the migratory capacity of MCF7-M cells significantly was reverted to the level of parental cells (Fig. 4i and j), indicating the implication of MG stress in this process. These data, generated using two experimental cancer models, support the conclusion that MG dicarbonyl stress promotes the migration and invasion of breast cancer cells. We selected cell migration ability to be used all along the following mechanistic exploration as a functional readout of MG stress in breast cancer cells.

As a major component of the tumor microenvironment, the ECM regulates many pathways in cancer cells, including TGF-β/bone morphogenic protein (BMP), PI3K/AKT, ERK, c-Jun N terminal kinase (JNK), Src-focal adhesion kinase (FAK) and Rho-GTPases [20]. Following the rationale that TGFβ is a key regulator of ECM synthesis in cancer, we first explored the impact of MG stress on the TGFβ pathway. Under basal conditions, neither GLO1-depleted nor control MDA-MB-231 cells showed detectable phosphorylated SMAD2/3, albeit, they were responsive to TGFβ as indicated by SMAD2/3 activation upon TGFβ stimulus (Fig. 5a). Interestingly, SMAD4 expression was significantly decreased in GLO1-depleted cells, suggesting that the canonical TGFβ pathway was dispensable upon MG stress induction in these cells (Fig. 5a).

We therefore explored alternative signaling pathways downstream of tyrosine kinase receptors and found that the level of phosphorylated MEK and ERK was increased in GLO1-depleted MDA-MB-231 cells (Fig. 5b). Knowing that MDA-MB-231 cells are mutated for KRAS and have a constitutive basal activation of MEK/ERK signaling pathway, we postulated that GLO1 silencing might be associated with the specific hyperactivation of this pathway. To verify this hypothesis, we next attempted to recapitulate this MG effect on MEK/ERK activity in MDA-MB-468 cells, a triple-negative breast cancer cell line that is wild-type for KRAS. Interestingly, MDA-MB-468 clones stably depleted for GLO1 (Additional file 2: Figure S5A) demonstrated a significant increase in MEK/ERK activation over the basal levels of control cells (Fig. 5b). Similar to MDA-MB-231 cells, we found that CD24 and lumican, two genes from the pro-metastatic signature, were increased and decreased, respectively, in GLO1-depleted MDA-MB-468 cells (Additional file 2: Figure S5B). These changes were also recapitulated upon MG treatment in control MDA-MB-468 cells (Additional file 2: Figure S5C). We were also able to recapitulate both enhanced migratory (Additional file 2: Figure S5D and E) and anchorage-independent growth (Additional file 2: Figure S5F and G) abilities in GLO1-depleted MDA-MB-468 cells that both consistently reverted on treatment with carnosine.

To consolidate the existence of a link between MG stress and MEK/ERK activation, we cultured MDA-MB-231 and MDA-MB-468 cells in the presence of increasing concentrations of exogenous MG. MG treatment induced P-MEK and P-ERK in both cell lines (Fig. 5c). Along the same line, carnosine prevented MEK/ERK activation in both shGLO1 MDA-MB-231 and MDA-MB-468 cells (Fig. 5d). Based on these data, we sought to corroborate the functional relevance of MG-mediated MEK/ERK hyperactivation with the enhanced migratory ability of GLO1-depleted breast cancer cells. Therefore, we treated GLO1-depleted MDA-MB-231 cells with U0126 MEK inhibitor. U0126 significantly prevented the increased migratory capacity observed for breast cancer cells under MG stress (Fig. 5e and f). Supporting this observation further, the expression of representative genes from the MG stress pro-metastatic signature, which were either induced (tenascin C, COL6A3) or repressed (lumican and COL4A3), reverted consistently in the presence of U0126 at the mRNA level in MDA-MB-231 cells (Fig. 5g). The data gathered so far demonstrate that MG dicarbonyl stress induces (hyper)activation of MEK/ERK signalization, independently of KRAS status, which sustains the regulation of pro-metastatic gene expression and migratory capacity of breast cancer cells.

To understand how (hyper)activation of the MEK/ERK signaling cascade in GLO1-depleted breast cancer cells relates to their metastatic potential, we first considered that MEK/ERK signaling could be mediated by the physical translocation of ERK in the nucleus. Using immunofluorescence, we excluded this possibility as GLO1-silenced cells showed P-ERK levels that were comparable to control cells using both MDA-MB-231 and MDA-MB-468 cells (Additional file 2: Figure S6A and B, respectively). Early studies involving expression of epitope-tagged SMAD1 indicated that it was generally involved in BMP, but not in TGFβ signaling [21, 22]. More recent data demonstrate that activated Ras/MEK pathway could participate in SMAD1 nuclear transcriptional activity [23, 24]. Based on that, we next evaluated SMAD1 expression and localization in GLO1-depleted MDA-MB-231 cells. As shown in representative immunofluorescence pictures, higher SMAD1 levels were detectable in the nucleus of GLO1-silenced MDA-MB-231 cells than in control cells (Fig. 6a). Phosphorylation of SMAD1 occurs at serine 206 (Ser 206) and serine 463/465 (Ser 463/465) following the activation of MAPK and BMP pathways, respectively [25]. In GLO1-depleted MDA-MB-231 and MDA-MB-468 cells (Fig. 6b), we evidenced a specific increase in P-SMAD1 (Ser 206) and a decrease in P-SMAD1/5 (Ser 463/465) that effectively points to cross-talk with MAPK signaling. We observed no significant change in SMAD1 and SMAD5 mRNA levels (Fig. 6c). GLO1 rescue in shGLO1#1 MDA-MB-231 cells reduced P-SMAD1 (Ser 206) (Additional file 2: Figure S7A). Consistently, MDA-MB-231 and MDA-MB-468 cells cultured in the presence of MG showed significant induction of total SMAD1 and P-SMAD1 (Ser 206) and decreased (Ser 463/465) (Fig. 6d). U0126 treatment further demonstrated the link with the MEK cascade as it strongly reduced the level of P-SMAD1 (Ser 206) in MDA-MB-231 cells (Fig. 6e). MDA-MB-468 cells, which are considered as high SMAD1 expressers when compared with other breast cancer cell lines [26], showed a similar pattern of SMAD1 serine phosphorylation upon MG treatment (Fig. 6d). Metastatic MCF7-M cells, bearing high endogenous MG stress, showed elevated total and phosphorylated SMAD1 levels when compared with parental MCF7 cells (Additional file 2: Figure S7B). SMAD1 inhibition (Additional file 2: Figure S7E) significantly decreased the migratory potential of MCF7-M cells (Additional file 2: Figure S7C and D).

Next, we further explored this new link between SMAD1 effector activation and MG stress signature. To this end, we evaluated the impact of GLO1 depletion on the expression of MG stress signature genes known to be SMAD1 targets. Seven out of 11 SMAD1 target genes, shown to be up-regulated under shGLO1 condition in RNASeq analysis, were significantly reduced upon SMAD1 silencing in GLO1-depleted MDA-MB-231 (Fig. 6f). The same experiment conducted on GLO1-depleted MDA-MB-468 cells revealed 5 out of 11 MG stress signature genes regulated by SMAD1, amongst which the PECAM1, GLI2 and B3GNT7 genes were common with MDA-MB-231 evaluation (Additional file 2: Figure S8A). Efficient silencing of SMAD1 was validated at the mRNA level in MDA-MB-231 (Fig. 6f) and in MDA-MB-468 cells (Additional file 2: Figure S8A). The silencing of SMAD1 in both GLO1-depleted cellular models had an impact on their migration ability and brought it back to control cell levels (Fig. 6g and h and Additional file 2: Figure S8B and C), as shown above for MCF7-M cells (Additional file 2: Figure S7B and C). Efficient silencing of SMAD1 was validated at the protein level (Fig. 6i and Additional file 2: Figure S8D). These results indicated that MG dicarbonyl stress induced the MEK/ERK/SMAD1 cascade (hyper)activation that controls the expression of pro-metastatic genes and impacts on migration in breast cancer cells.

Levels of ERK phosphorylation are dictated by the coordinated activity of protein kinases and phosphatases [27]. The (hyper)activation of MEK/ERK evidenced in breast cancer cells under MG stress led us to test the possibility that this persistent stimulation may be due to a defect in MAPK phosphatase expression in these cells. RNASeq data indeed showed decreased expression of dual-specificity (DUSPs) and phosphoprotein (PPP) phosphatase genes in GLO1-depleted cells (Additional file 2: Table S2). We quantified the mRNA levels of nine PPPs (either catalytic, structural or regulatory subunits) (Additional file 2: Figure S9A) and seven DUSPs (Fig. 7a and Additional file 2: Figure S9B) in MDA-MB-231 and MDA-MB-468 cells. DUSPs control the duration and magnitude of MAPK signaling activities. We selected DUSP1, 5, 8 and 16 for further validation because of their consistent down-regulation in MDA-MB-231 (Fig. 7a) and MDA-MB-468 cells (Additional file 2: Figure S9B) upon silencing with 2 GLO1 shRNAs. We validated the down-regulation of DUSP5 and 8 at the protein level in both cell lines (Fig. 7b). Following this, we focused on DUSP5 loss because of its known specificity for ERK1/2 and its significant decrease upon MG treatment at the mRNA and protein levels (Fig. 7c and d, respectively) in MDA-MB-231 and MDA-MB-468 cells. To gain insights into this new association between DUSP5 down-regulation and MG stress, we overexpressed DUSP5 in GLO1-depleted MDA-MB-231 and MDA-MB-468 cells. Under these conditions, we observed a significant P-ERK decrease associated with reduced SMAD1 and P-SMAD1 expression in MDA-MB-231 (Fig. 7e) and MDA-MB-468 cells (Fig. 7f). Upon DUSP5 overexpression, both GLO1-depleted cells showed a decreased migratory capacity (Fig. 7g and h and Additional file 2: Figure S10A and B) thus functionally linking DUSP5 regulation occurring under MG stress with pro-metastatic features in breast cancer cells. Everything included, we have then demonstrated that MG dicarbonyl stress endows breast cancer cells with genetic changes, notably affecting (i) ECM matrix reorganization, (ii) MEK/ERK cascade via cross-talk with SMAD1 transcriptional activity and (iii) DUSPs inhibition, which ultimately promoted their migratory and metastatic potential (Fig. 7i).